Solid Organ Transplantation Self-Assessment Program (SOTSAP) (L269219)
ACPE Numbers: Various – see listing below
Release Date: November 16, 2026
Expiration Dates: November 16, 2027
Activity Type: Application-based
CE Credits: 21.5 contact hours (BPS and ACPE)
Activity Fee: $88 (ASHP member); $132 (non-member)
Activity Overview
This course is intended for board-certified pharmacists in need of recertification credit and is designed based on the content outline developed by Board of Pharmacy Specialties (BPS). The course consists of 9 topics (see table below) and provides 21.5 contact hours of continuing pharmacy education and/or recertification credit.
Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.
These activities are part of the ACCP and ASHP professional development program for BCTXP recertification approved by the BPS.
Accreditation
![]() |
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation. |
![]() |
The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education. |
Target Audience
The target audience for Solid Organ Transplant Self-Assessment Program (SOTSAP) 2026 and is board-certified and advanced level solid organ transplant clinical pharmacists.
Recertification Credit
Board-certified pharmacists are eligible to receive up to 21.5 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.
ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.
![]()
ACCP and ASHP are approved by BPS as a provider for the recertification of BCTXP.
|
Learning Activity |
Passing Score |
Credit Information |
|
Chapter: Updates in Desensitization (ABOi) |
80% |
BPS: BCTXP |
|
Chapter: Updates in Desensitization (HLA) |
60% |
BPS: BCTXP |
|
Chapter: Cardiac Allograft Vasculopathy and Chronic Lung Allograft Dysfunction |
80% |
BPS: BCTXP |
| Chapter: Respiratory Viral Infections |
86% |
BPS: BCTXP |
| Chapter: Expanding the Donor Pool |
86% |
BPS: BCTXP |
| Chapter: Donor and Recipient Pain Management |
86% |
BPS: BCTXP |
| Chapter: Technology for Care Delivery and Patient Education |
73% |
BPS: BCTXP |
| Case Series: Pediatric Transplant and Infection |
83% |
BPS: BCTXP |
|
|
83% |
2.5 Contact Hour BPS: BCTXP |
Learning Objectives
Chapter: Updates in Desensitization (ABOi)
ACPE: 0217-9999-26-233-H01-P
- Discover recent advances in the literature on ABO-incompatible (ABOi) transplantation, including alternative strategies, novel antibody testing methods, complications, and outcomes.
- Evaluate the effectiveness and suitability of current desensitization therapies in the context of ABOi transplantation.
- Distinguish emerging therapies in the pipeline for their potential application in ABOi transplantation.
- Assess clinical scenarios involving patients with ABOi living donors to determine transplant eligibility and challenges.
- Develop a personalized desensitization plan for a patient undergoing evaluation for ABOi transplantation.
Chapter: Updates in Desensitization (HLA)
ACPE: 0217-9999-26-234-H01-P
- Analyze the literature using novel immunosuppressive agents as monotherapy or combination therapy with respect to their recent use in highly sensitized transplant candidates.
- Develop a desensitization plan for a highly sensitized transplant candidate according to the recent literature.
- Develop a plan for detecting and potentially treating early antibody-mediated rejection in a transplant recipient undergoing desensitization.
Chapter: Cardiac Allograft Vasculopathy and Chronic Lung Allograft Dysfunction
ACPE: 0217-9999-26-235-H01-P
- Analyze the underlying pathophysiology, clinical presentation, and identifiable risk factors contributing to the development and progression of cardiac allograft vasculopathy (CAV) and chronic lung allograft dysfunction (CLAD).
- Assess the usefulness of different diagnostic modalities for detection of CAV and CLAD and develop a monitoring plan.
- Evaluate the benefits and gaps of the pharmacotherapy agents used to prevent and manage CAV and CLAD.
- Construct a pharmacotherapy plan for patients with CAV and CLAD.
Chapter: Respiratory Viral Infections
ACPE: 0217-9999-26-236-H01-P
- Evaluate and interpret respiratory virus diagnostic testing.
- Assess indications for respiratory viral prophylaxis in solid organ transplant recipients (SOTRs).
- Devise and justify the use of therapies for the treatment of respiratory viral infections (RVIs).
- Compose individualized immunosuppressive regimens in the context of concomitant RVI.
- Develop monitoring plans to identify and manage complications of RVIs.
Chapter: Expanding the Donor Pool
ACPE: 0217-9999-26-237-H01-P
- Justify the clinical rationale for using hepatitis C virus (HCV)-, hepatitis B virus (HBV)-, and HIV-positive donor organs to expand the solid organ transplant pool.
- Develop evidence-based strategies to manage transplantation of HCV-positive donor organs including appropriate candidate selection, use of direct-acting antivirals, and posttransplant monitoring, to optimize recipient outcomes and mitigate risks of viral transmission and graft complications.
- Formulate management strategies for transplantation of HBV-positive donor organs, incorporating pretransplant vaccination, antiviral prophylaxis, and posttransplant surveillance, to reduce transmission risk and optimize long-term recipient outcomes.
- Design management approaches for HIV-positive donor to HIV-positive recipient transplantation, emphasizing antiretroviral regimen optimization, drug-drug interaction monitoring, and infection surveillance, to ensure graft function and recipient safety.
- Discover the ethical, legal, and policy considerations surrounding the use of HCV-, HBV-, and HIV-positive donor organs.
Chapter: Donor and Recipient Pain Management
ACPE: 0217-9999-26-238-H01-P
- Distinguish the potential risks associated with pretransplant opioid use on posttransplant outcomes, including graft survival and patient mortality.
- Assess the differences in mechanisms of multimodal pain agents and how they differ from opioids.
- Demonstrate how to apply multimodal analgesic strategies (eg, transversus abdominis plane [TAP] block, acetaminophen, gabapentin) in creating a pain management plan for living donation.
- Assess the efficacy and safety outcomes of opioid minimization protocols across different organ transplant types.
- Develop an institutional policy framework for opioid stewardship in solid organ transplantation, integrating patient education, preoperative risk assessment, and discharge prescribing guidelines.
Chapter: Technology for Care Delivery and Patient Education
ACPE: 0217-9999-26-239-H01-P
- Analyze the evolving role of the transplant pharmacist to account for how technology integration enhances medication management, care coordination, and patient education across the transplant continuum.
- Evaluate how telepharmacy, electronic health record optimization, clinical decision support, and remote monitoring technologies can be applied to optimize safety, efficiency, and continuity of transplant care.
- Assess the effectiveness of digital education platforms, mobile applications, and gamified learning tools in improving transplant recipient comprehension, engagement, and medication adherence.
- Design and devise technology-driven strategies to integrate into the transplant care workflow that enhance interdisciplinary collaboration, optimize pharmacotherapy management, and measure patient-centered outcomes.
- Analyze and justify approaches to overcome barriers to technology adoption—such as data privacy, patient access, and provider resistance—while maintaining ethical and regulatory compliance.
Case Series: Pediatric Transplant and Infection
ACPE: 0217-9999-26-240-H01-P
- Assess changes to recommended immunizations for pediatric solid organ transplant (SOT) recipients and candidates.
- Evaluate the use of newer antimicrobial agents, vaccines, and antibodies in pediatric SOT recipients and candidates at risk of infectious complications.
- Analyze the current recommendations on the management of cytomegalovirus (CMV) in pediatric SOT recipients.
- Design treatment plans for pediatric SOT recipients with BK virus in accordance with the current guideline recommendations.
Case Series: Pregnancy and Reproductive Health
ACPE: 0217-9999-26-241-H01-P
- Assess the benefits and risks of available contraceptive methods for a solid organ transplant recipient.
- Construct a reproductive-health counseling plan for a sexually active solid organ transplant recipient.
- Evaluate the maternal, graft, and fetal outcomes of pregnancy after solid organ transplant.
- Design a safe immunosuppression regimen and monitoring plan for a solid organ transplant recipient during pregnancy and breastfeeding.
Faculty
Disclosures
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ACCP and ASHP require that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
Consultancies: Marissa M. Brokhof (Visante Consulting)
Grants: Jamie J. Benken (Innoviva); Elisabeth Kincaide (Merck); Emily Sartain (Merck)
Honoraria: Kellie J. Goodlet (Merck)
Stocks: Erika Meredith (Abbott Laboratories)
Methods and CE Requirements
Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:
- Complete the attestation statement
- Review all content
- Complete and pass the assessments
- Complete the evaluations
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.
Development
ACCP and ASHP collaborate on solid organ transplant pharmacy activities.


